Report cover image

Global Rabies Vaccine Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Jul 16, 2025
Length 191 Pages
SKU # APRC20280466

Description

Summary

According to APO Research, the global Rabies Vaccine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Rabies Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Rabies Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Rabies Vaccine market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Rabies Vaccine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Rabies Vaccine market include Changsheng, Yisheng, VACN, Prcmise, Chengda, BCHT, Hissen, Sanofi-Pasteur and GSK (Novartis), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Rabies Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Rabies Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Rabies Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Rabies Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Rabies Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Rabies Vaccine sales, projected growth trends, production technology, application and end-user industry.

Rabies Vaccine Segment by Company

Changsheng
Yisheng
VACN
Prcmise
Chengda
BCHT
Hissen
Sanofi-Pasteur
GSK (Novartis)
Rabies Vaccine Segment by Type

Vero Cell Rabies Vaccine
Chick Embryo Cell Rabies Vaccine
BHK
Others
Rabies Vaccine Segment by Application

Pre-exposure Prophylaxis
Post-exposure Prophylaxis
Rabies Vaccine Segment by Region

North America

United States
Canada
Europe

Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific

China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America

Mexico
Brazil
Argentina
Middle East & Africa

Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Rabies Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Rabies Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Rabies Vaccine significant trends, drivers, influence factors in global and regions.
6. To analyze Rabies Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rabies Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rabies Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rabies Vaccine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Rabies Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Rabies Vaccine industry.
Chapter 3: Detailed analysis of Rabies Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Rabies Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Rabies Vaccine in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

191 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Rabies Vaccine Sales Value (2020-2031)
1.2.2 Global Rabies Vaccine Sales Volume (2020-2031)
1.2.3 Global Rabies Vaccine Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Rabies Vaccine Market Dynamics
2.1 Rabies Vaccine Industry Trends
2.2 Rabies Vaccine Industry Drivers
2.3 Rabies Vaccine Industry Opportunities and Challenges
2.4 Rabies Vaccine Industry Restraints
3 Rabies Vaccine Market by Company
3.1 Global Rabies Vaccine Company Revenue Ranking in 2024
3.2 Global Rabies Vaccine Revenue by Company (2020-2025)
3.3 Global Rabies Vaccine Sales Volume by Company (2020-2025)
3.4 Global Rabies Vaccine Average Price by Company (2020-2025)
3.5 Global Rabies Vaccine Company Ranking (2023-2025)
3.6 Global Rabies Vaccine Company Manufacturing Base and Headquarters
3.7 Global Rabies Vaccine Company Product Type and Application
3.8 Global Rabies Vaccine Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Rabies Vaccine Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Rabies Vaccine Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Rabies Vaccine Market by Type
4.1 Rabies Vaccine Type Introduction
4.1.1 Vero Cell Rabies Vaccine
4.1.2 Chick Embryo Cell Rabies Vaccine
4.1.3 BHK
4.1.4 Others
4.2 Global Rabies Vaccine Sales Volume by Type
4.2.1 Global Rabies Vaccine Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Rabies Vaccine Sales Volume by Type (2020-2031)
4.2.3 Global Rabies Vaccine Sales Volume Share by Type (2020-2031)
4.3 Global Rabies Vaccine Sales Value by Type
4.3.1 Global Rabies Vaccine Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Rabies Vaccine Sales Value by Type (2020-2031)
4.3.3 Global Rabies Vaccine Sales Value Share by Type (2020-2031)
5 Rabies Vaccine Market by Application
5.1 Rabies Vaccine Application Introduction
5.1.1 Pre-exposure Prophylaxis
5.1.2 Post-exposure Prophylaxis
5.2 Global Rabies Vaccine Sales Volume by Application
5.2.1 Global Rabies Vaccine Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Rabies Vaccine Sales Volume by Application (2020-2031)
5.2.3 Global Rabies Vaccine Sales Volume Share by Application (2020-2031)
5.3 Global Rabies Vaccine Sales Value by Application
5.3.1 Global Rabies Vaccine Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Rabies Vaccine Sales Value by Application (2020-2031)
5.3.3 Global Rabies Vaccine Sales Value Share by Application (2020-2031)
6 Rabies Vaccine Regional Sales and Value Analysis
6.1 Global Rabies Vaccine Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Rabies Vaccine Sales by Region (2020-2031)
6.2.1 Global Rabies Vaccine Sales by Region: 2020-2025
6.2.2 Global Rabies Vaccine Sales by Region (2026-2031)
6.3 Global Rabies Vaccine Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Rabies Vaccine Sales Value by Region (2020-2031)
6.4.1 Global Rabies Vaccine Sales Value by Region: 2020-2025
6.4.2 Global Rabies Vaccine Sales Value by Region (2026-2031)
6.5 Global Rabies Vaccine Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Rabies Vaccine Sales Value (2020-2031)
6.6.2 North America Rabies Vaccine Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Rabies Vaccine Sales Value (2020-2031)
6.7.2 Europe Rabies Vaccine Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Rabies Vaccine Sales Value (2020-2031)
6.8.2 Asia-Pacific Rabies Vaccine Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Rabies Vaccine Sales Value (2020-2031)
6.9.2 South America Rabies Vaccine Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Rabies Vaccine Sales Value (2020-2031)
6.10.2 Middle East & Africa Rabies Vaccine Sales Value Share by Country, 2024 VS 2031
7 Rabies Vaccine Country-level Sales and Value Analysis
7.1 Global Rabies Vaccine Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Rabies Vaccine Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Rabies Vaccine Sales by Country (2020-2031)
7.3.1 Global Rabies Vaccine Sales by Country (2020-2025)
7.3.2 Global Rabies Vaccine Sales by Country (2026-2031)
7.4 Global Rabies Vaccine Sales Value by Country (2020-2031)
7.4.1 Global Rabies Vaccine Sales Value by Country (2020-2025)
7.4.2 Global Rabies Vaccine Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.5.2 USA Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Canada Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.8.2 Germany Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.9.2 France Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.9.3 France Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.11.2 Italy Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.12.2 Spain Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.13.2 Russia Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.16.2 China Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.16.3 China Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.17.2 Japan Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.19.2 India Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.19.3 India Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.20.2 Australia Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.24.2 Chile Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.26.2 Peru Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.28.2 Israel Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.29.2 UAE Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.31.2 Iran Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Rabies Vaccine Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Rabies Vaccine Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Rabies Vaccine Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 Changsheng
8.1.1 Changsheng Comapny Information
8.1.2 Changsheng Business Overview
8.1.3 Changsheng Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.1.4 Changsheng Rabies Vaccine Product Portfolio
8.1.5 Changsheng Recent Developments
8.2 Yisheng
8.2.1 Yisheng Comapny Information
8.2.2 Yisheng Business Overview
8.2.3 Yisheng Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.2.4 Yisheng Rabies Vaccine Product Portfolio
8.2.5 Yisheng Recent Developments
8.3 VACN
8.3.1 VACN Comapny Information
8.3.2 VACN Business Overview
8.3.3 VACN Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.3.4 VACN Rabies Vaccine Product Portfolio
8.3.5 VACN Recent Developments
8.4 Prcmise
8.4.1 Prcmise Comapny Information
8.4.2 Prcmise Business Overview
8.4.3 Prcmise Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.4.4 Prcmise Rabies Vaccine Product Portfolio
8.4.5 Prcmise Recent Developments
8.5 Chengda
8.5.1 Chengda Comapny Information
8.5.2 Chengda Business Overview
8.5.3 Chengda Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.5.4 Chengda Rabies Vaccine Product Portfolio
8.5.5 Chengda Recent Developments
8.6 BCHT
8.6.1 BCHT Comapny Information
8.6.2 BCHT Business Overview
8.6.3 BCHT Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.6.4 BCHT Rabies Vaccine Product Portfolio
8.6.5 BCHT Recent Developments
8.7 Hissen
8.7.1 Hissen Comapny Information
8.7.2 Hissen Business Overview
8.7.3 Hissen Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.7.4 Hissen Rabies Vaccine Product Portfolio
8.7.5 Hissen Recent Developments
8.8 Sanofi-Pasteur
8.8.1 Sanofi-Pasteur Comapny Information
8.8.2 Sanofi-Pasteur Business Overview
8.8.3 Sanofi-Pasteur Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.8.4 Sanofi-Pasteur Rabies Vaccine Product Portfolio
8.8.5 Sanofi-Pasteur Recent Developments
8.9 GSK (Novartis)
8.9.1 GSK (Novartis) Comapny Information
8.9.2 GSK (Novartis) Business Overview
8.9.3 GSK (Novartis) Rabies Vaccine Sales, Value and Gross Margin (2020-2025)
8.9.4 GSK (Novartis) Rabies Vaccine Product Portfolio
8.9.5 GSK (Novartis) Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Rabies Vaccine Value Chain Analysis
9.1.1 Rabies Vaccine Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Rabies Vaccine Sales Mode & Process
9.2 Rabies Vaccine Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Rabies Vaccine Distributors
9.2.3 Rabies Vaccine Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.